Horizon Therapeutics plc last week announced results of a U.S. physician survey showing that endocrinologists and ophthalmologists perceive Thyroid Eye Disease (TED) to have a significant burden on their patients’ quality of life (QOL). These findings were presented at a poster session at the AACE 29th Annual Scientific & Clinical Congress as well as in a special supplement of Endocrine Practice.
TED is a serious, progressive and vision-threatening rare autoimmune disease associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain, inflammation and facial disfigurement.
The evaluation was conducted to better understand how U.S. endocrinologists and ophthalmologists perceive the QOL of their TED patients. A total of 181 physicians (73 endocrinologists and 108 ophthalmologists) responded to the online survey, reporting insights from 714 total patients with moderate to severe TED. The evaluation addressed topics including overall QOL, ability to attend work/school, ability to function in social situations, ability to participate and enjoy day-to-day activities, ability to drive and psychological well-being.
Participants reported considerable overall QOL impact on TED patients (overall rating of 4.1 out of a maximum of 7). Importantly, TED patients had nearly double the rates of anxiety and depression than the general U.S. adult population (36.4 percent vs. 18.9 percent). Vision problems caused by TED, including strabismus (misaligned eyes), diplopia (double vision) and ocular pain, were some of the factors that had the highest impact on QOL. These factors are also often drivers of mobility restrictions or occupational disability.
“This analysis shows that physicians are acutely aware of the significant burden TED has on their patients, including not only the painful eye symptoms, but also the major impact on mental health, social interactions, driving and employment,” said Yao Wang M.D., neuro-ophthalmology and oculoplastics specialist, Cedars-Sinai Medical Center. “With new therapeutic options becoming available, this evaluation reinforces the urgent need to manage the serious effects of TED and preserve quality of life as much as possible to protect patients’ well-being.”
“These data reinforce that physicians understand the onerous burden of this challenging disease and the urgent need to help improve patients’ daily lives,” said Jeffrey W. Sherman, M.D., FACP, executive vice president, chief medical officer, Horizon. “This is why we are so focused on urgently supporting people living with TED, not only with new therapies, but also by providing their physicians with tools and resources to help improve patient quality of life.”
Full news release: https://ir.horizontherapeutics.com/news-releases/news-release-details/us-physician-survey-illustrates-devastating-impact-thyroid-eye